Latigo Biotherapeutics Reports the First Patient Dosing with LTG-305 in its P-I Study for Non-Opioid Treatment of Pain
Shots:
- Latigo Biotherapeutics has dosed the first patient with LTG-305 under its P-I clinical evaluation for non-opioid treatment of pain
- The P-I study will assess the safety, tolerability & PK profile of LTG-305 in healthy subjects through single-ascending (SAD) arm under which they will receive increasing single doses and multiple-ascending dose (MAD) arm involving multiple doses over a defined period. Topline data is expected in mid-2025
- LTG-305 is a Nav1.8 inhibitor developed to treat chronic pain at its source, offering a non-opioid alternative with fewer side effects like addiction, dizziness, and somnolence. It targets pain by selectively inhibiting the Nav1.8 sodium channel, crucial for pain signal transmission
Ref: Latigo Biotherapeutics | Image: Latigo Biotherapeutics
Related News:- Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
